Executive Profiles

Executive Roundtable

Leadership

Press Releases

Corporate Communications

Healthcare Access

Patient Education

Telehealth

Direct-to-Consumer

Funding

Partnerships

Emerging Biopharma

Finance

Industry Trends

IR Licensing and Partnerships

Patient Access

Pricing

Strategy

Market Access

Clinical Data

Patient Advocacy

Pharmacovigilance

Medical Affairs

R&D/Clinical Trials

Supply Chain

Sustainability

Technology

Operations

DE&I

Patient Engagement

Global

Legal

Regulatory

Campaigns

DTC Marketing

Medical Education

Sales & Marketing

News

Pharma Pulse

Academy

Multimedia

Editorial Podcasts

Editorial Videos

Profiles in Medicine

Conferences

Conference Coverage

Conference Listing

Publications

Pharmaceutical Executive

Partner Perspectives

Resources

Content Engagement Hubs

E-Books

Events

Webcasts

Whitepapers

Subscribe

Master the Science of Success through aspirational coverage for executive-level decisions, leadership, management, strategy and commercialization professionals.

About

Advertise

Contact Us

Editorial Board

Editorial Submission Guidelines

Do Not Sell My Personal Information

Privacy Policy

Terms and Conditions

LinkedIN

Instagram

Facebook

Threads

Bluesky

Spotlight

Pharmaceutical Executive APEX Awards 

Latest Executive Roundtables

Topic

Sales and Marketing

1rem

LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, discusses strategies to address underrepresentation in phase III psoriasis trials. She also talks about Takeda's partnerships with community stakeholders like Inside Edge, Black Health Matters, and Hispanic Communication Global Network to help improve engagement, address operational barriers by incorporating multicultural imagery, and prioritize sites with diverse patient demographics. She also explains how they've enhanced investigator diversity through educational sessions and multilingual toolkits, and how Takeda aims to expand these efforts globally.

Podcasts

LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials. 

Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

 podcast episode, UpScriptHealth founder and CEO Peter Ax discusses:

The impact of tariffs on the pharmaceutical industry, highlighting branded and generics medications

How tariffs could lead to strategic supply chain changes, including potential US manufacturing shifts

How digital health platforms can help potentially offset tariff impacts

The importance of telehealth in ensuring medication availability

Strategic partnerships between digital health platforms and pharma companies to improve patient care and access

Peter Ax, founder & CEO of UpScriptHealth, discusses the impact of tariffs on the pharmaceutical industry and how digital health platforms could potentially help offset them.

Tariffs and Drug Prices: Understanding the Impact on Pharmaceuticals

 podcast, Jennifer Butler, chief commercial officer of Pleio, discusses:

The threat of misinformation to public health and how emotional appeal plays a part.

Where patients are turning for trustworthy health information.

Strategies that can be used to verify information.

Pharma's role in helping to ensure patients have access to health insights they can trust.

Why the industry is turning to peer-to-patient platforms, trusted patient communities, and pharmacies to educate patients.

What kind of role regulatory agencies should play in the battle against misinformation.

Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.

The Misinformation Maze: Navigating Public Health in the Digital Age

 Podcast, CEO and Founder of Sooth, Ian Baer, is back to discuss:

Why people trust friends and influencers over companies

Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.

Navigating Distrust: Pharma in the Age of Social Media

In this episode of the Pharmaceutical Executive podcast, Bill Grambley, CEO of AllazoHealth, explores:

How AI can potentially revolutionize patient engagement and adherence

Utilizing patient-level data and predictive modeling

How AI can identify individual needs and preferences

The importance of ethical considerations and data privacy when leveraging AI in healthcare

Bill Grambley, CEO of AllazoHealth, delves into the potential of AI to revolutionize patient engagement and adherence.

Revolutionizing Patient Adherence: Leveraging AI for Personalized Engagement

The high-stakes nature of cancer care, coupled with rapid scientific advancements and increasing payer and regulatory pressures, demands a specialized approach beyond traditional market access strategies. 

Oncology Brands Face Uniquely Complex Market Access Challenges: A Specialized Approach for Commercial Success

Delivering Personalized Experiences at Scale: A Fresh Look at Customer Centricity

Polypharmacy, biosimilars, and GLP-1s among the evolving trends likely to play out in the pharmacy benefits space.  

The Shifting Pharmacy Landscape in 2025

Kimberley Chiang, vice president of biopharma commercial solutions at CoverMyMeds, discusses ethical considerations surrounding AI use in medication access, and how the industry can ensure that these technologies are used responsibly and equitably.

Ethical Considerations for AI Use in Medication Access

 video interview, Kimberley Chiang, vice president of biopharma commercial solutions at CoverMyMeds, discusses "The 2025 Medication Access Report." She highlights gaps in data-sharing and cross-functional collaboration as major bottlenecks that cause delays, rework, and increased patient burden. Chiang shares that only 3% of patients utilize support programs due to a lack of awareness. A large majority of the report's respondents plan to expand funding for patient support programs within the next 5 years due to large number of new therapies expected to come to market.

Pharmaceutical Executive: With the rapid advancement of AI, what are the ethical considerations surrounding its use in medication access, and how can the industry ensure that these technologies are used responsibly and equitably?


Ethical considerations with the use of any technology tool that is going to replace human decision making is something that we are quite focused on as an organization. We believe in responsibility and that AI should only be a complementary tool until we are very confident in the fair and unbiased nature of the AI and the diverse data sets that it’s pulling from.

For today and the near future, we believe the best position for AI is where technology enhances clinical support. The human component of care continues to be the most important element of making sure that the right clinical decisions are made for patients. We want to make sure that AI is used to support, not replace. The human touch in healthcare should persist in the most relevant clinical support services going forward.

We also believe in the protection of private information. Building those diverse data sets while maintaining patient privacy is a critical element to consider as an industry. While thinking about patient privacy, we also must think about transparency in decision making. A patient should know how a decision was made relative to their care. They should fully understand and be able to ask questions about how the process solicited this type of support for them.

The ability to protect privacy and maintain transparency in the decision-making process for patients is a critical factor that the industry needs to think about.

Videos

Kimberley Chiang, vice president of biopharma commercial solutions at CoverMyMeds, discusses ethical considerations surrounding AI use in medication access and how the industry can ensure that these technologies are used responsibly and equitably.

Kimberley Chiang, vice president of biopharma commercial solutions at CoverMyMeds, discusses how the industry leverages data and technology to identify and address affordability issues before they become a barrier to patient access.

Proactively Identifying & Addressing Affordability Issues with Predictive Analytics

Pharmaceutical Executive: How can the industry leverage data and technology to proactively identify and address affordability issues before they become a barrier to patient access? What role does predictive analytics play in this?


 The ability to be proactive in identifying and addressing those gaps requires a centralized data system and a greater ecosystem. The ability to leverage data requires that data to be comprehensive. Predictive analytics will run on strong data models, and in order to have those, you need a seamless experience.

How do we capture data along the patient journey, and how do we ensure that predictive analytics will help us analyze that data? It all starts with the ability to streamline the data. If we don’t begin to bring data sources together in real and important ways, we will not be able to properly allocate our resources and spending in pharma. There will be some forecasting and assumptions, but with some real-world data (RWD) integrated.

Think about the addition of an integrated data model with RWD and what that could do for better predictive analytics. Our assumptions would be lowered, and our predictions would be better. We would have optimized predictability for where the funding needs to be directed.

The second piece of that is you have better clinical outcomes if you can identify in advance. You will not have patients walking away from their prescriptions, which continues to be a challenge. We are also seeing significant increases in claims denials. About 73% of claims are denied. What do we do when claims come back denied?

With predictive analytics, there are affordability and co-pay types of expansion. There’s also focus and energy around overturning claim denials. How do we ensure that the claim was denied for righteous reasons? The ability to have all of the data integrated and run it through predictive analytics alongside RWD would help us improve clinical outcomes. Those patients will not be denied medication that they need and rightfully deserve.

Doing all of this more efficiently will remove costs from the ecosystem. There is significant fragmentation in all of the processes. To bring all of that data together to understand the market access for a single brand launch, bio-pharmas must piece together all of that information. Bringing data together and using predictive analytics with strong data models will help these companies do so more efficiently. It will take costs out of the system and speed patients onto the right medications. Healthcare providers will also spend less time waiting for the patient to get approved.

Kimberley Chiang, vice president of biopharma commercial solutions at CoverMyMeds identifies innovative strategies and solutions for addressing the rising cost of medications and improving patient access.

Strategies to Address Rising Medication Costs & Improve Patient Access

Pharmaceutical Executive: Beyond traditional copay assistance programs, what innovative solutions or strategies does the report show are emerging to address the rising cost of medications and improve patient access?


 Beyond traditional copay programs, innovating in this area is going to be critical in the next few years. The challenge is to rethink the journey. We need to see patients in more dimensions than we’re seeing them today. We need to see more than just their ability to pay. There are more things that are critical drivers of adherence and access to medication that should be considered along the patient journey.

We are big advocates for a comprehensive view of the patient, expanding that view, and then bringing that into the data. For folks that are bringing and designing projects and financial support programs, this means figuring out how to design those dimensions in to ensure that we’re not just looking at pure affordability. This means going beyond asking if they have coverage and what their copay is. Expanding beyond that is one of the most critical elements to evolving the state of patient affordability programs.

The way to do that is in the design. Traditional co-pay programs only look at two dimensions: do you have a copay and can you afford to pay. We have to look at a couple of different elements. Using patient education as an example, we can educate patients to self-advocate and declare the challenges they might be experiencing in a community. The ability for a person who’s living on their own to pay for a taxi to take them to receive their medication at a distant clinic impacts whether they even consider taking the medication.

How can we look at all of the dimensions of a patient and plan those assessments into program design to ensure adherence from the beginning? We think of adherence as perpetually being on the medication and living well. A lot of the work in the past 5 years has been around structing adherence support programs for patients who have agreed to go on a prescription and have no affordability issues.

Addressing adherence issues at the very beginning is a change to that paradigm. We’re moving off of the linear patient journey and looking at dimensionalizing the patient experience. How do we plan forward and proactively identify those gaps? What algorithms can we use with predicative analytics to look at a patient’s profile and show what a support program looks like that has the best chances of that patient getting, staying on, and doing well with medication? What levers do we need to play with in a support program to ensure that the patient’s holistic needs are managed? This includes educating them, managing travel concerns, and pre-planning all of that.

The journey doesn’t look like a straight line. We need to constantly review if the patient’s needs have changed as their journey improves or time passes. Are there ways to intervene early using predictive analytics? Should we intervene with certain types of patients on certain dimensions early in their healthcare journey to have the best outcomes? This is the important element in designing patient support programs. We’re going to spend the money, but how do we do that differently going forward?

The other element is bringing the concept of digital healthcare forward so that patients have digital solutions and tools at their fingertips. Patients today can do all of their other needs on their phones. This is the mobile phone culture which we talk about quite extensively in the report. However, a patient who’s experiencing illness can’t pick up their phone to search for help with their questions or find affordability options. They don’t have tools to monitor where they should be in their healthcare journey. There is an overwhelming appetite for innovative tools.

However, digital solutions come with a bit of a paradox: more digital solutions mean less human touch. The industry is going to be challenged with striking that balance between putting efficient digital tools in the hands of the patients while also allowing for the human touch when it’s needed. That’s a balance that we need to strike, and it’s going to be a challenge that the industry is going to face. Eighty percent of patients say they prefer something digital, but how many are actually using digital tools when available?

What we need to monitor as we bring these brilliant, innovative solutions forward is the balance with the patient’s access to a human touch.

Kimberley Chiang, vice president of biopharma commercial solutions at CoverMyMeds, identifies innovative strategies and solutions for addressing the rising cost of medications and improving patient access.

Kimberley Chiang, vice president of biopharma commercial solutions, CoverMyMeds, highlights gaps in data sharing and cross-functional collaboration as major bottlenecks that are causing delays, rework, and increased patient burden.

The 2025 Medication Access Report: Biggest Bottlenecks for Patients

 video interview, Kimberley Chiang, vice president of biopharma commercial solutions at CoverMyMeds, discusses "The 2025 Medication Access Report.

 She highlights gaps in data-sharing and cross-functional collaboration as major bottlenecks that cause delays, rework, and increased patient burden. Chiang shares that only 3% of patients utilize support programs due to a lack of awareness. A large majority of the report's respondents plan to expand funding for patient support programs within the next 5 years due to large number of new therapies expected to come to market. The report emphasizes the need for interoperability to streamline data and improve patient outcomes.

Pharmaceutical Executive: "The 2025 Medication Access Report" highlights significant fragmentation due to gaps in data-sharing and cross-functional collaboration. Can you elaborate on the most critical areas where these gaps are causing the biggest bottlenecks for patients? Specifically, what are the tangible effects you've observed on patient timelines and outcomes?


The lack of cross-functional collaboration in our industry adds fragmentation, and the seamlessness of the flow of data and the patient experience is impacted. Whenever we impact seamlessness, we impact the data that is arriving to help us make decisions or anticipate gaps in patient care. It causes delays, rework, and for the burden to fall on the patient to piece together all the elements to find the best way to cover some of the barriers that they’re experiencing in their own healthcare ecosystem.

The industry needs a cohesive and efficient approach that takes cost out of the system and adds data at the right time to help HCPs make the right decisions. We need to get out of our silos because we’re still in our own way. The lack of a clear view drives delays, creates barriers, and doesn’t look at the holistic needs of the patient.

For example, pharmacies and providers see certain needs, and pharma is paying for patient support programs to provide other needs for patients. However, we’re not talking to each other, and that’s where the challenge lies. If we’re looking for the best outcomes for patients and the urgency to get them the medications they need quickly and efficiently with all the education and support for the patient journey, we need to improve integration.

The second element is the knowledge gap. Forty-six percent and 52% of providers don’t know what’s out there for patients. They may be able to identify a gap, but they don’t know where to go to fill that gap. Therefore, the pieces still don’t get put together in that puzzle for the patient and causes delays in looking up what’s available for that patient in their community.

The knowledge gap worsens the delay and puts the burden back on the patient to put together the pieces of their healthcare ecosystem themselves.

The pharma industry is committed to increasing the funding for patient-support programs. But if patients don’t know about them, the utilization stays at about 3%. The majority of the biopharma customers we talked to said that in 5 years, they plan to expand support and funding for these programs. That’s based on the fact that important new therapies are coming to market in the next 5 years and 75% of them have increased complexity because they’re in the specialty realm.

Complexity drives gaps and needs. If we don’t bring this ecosystem together and have data sharing across the portfolio to reduce fragmentation, we are going to continue to see delays which effectively reduce outcomes for patients.

Kimberley Chiang, vice president of biopharma commercial solutions at CoverMyMeds, highlights gaps in data sharing and cross-functional collaboration as major bottlenecks that are causing delays, rework, and increased patient burden.

Peter Ax, Founder & CEO of UpScriptHealth, explores how tariffs could affect the availability and accessibility of specific medications, particularly for patients relying on direct-to-patient telehealth.

Potential Tariff Impact on Availability & Accessibility of Medications for Telehealth Patients

 Video Interview, Peter Ax, Founder & CEO of UpScriptHealth, discusses the impact of tariffs on the pharmaceutical industry, highlighting that tariffs will initially affect pharmaceutical companies, particularly those dealing with branded medications and generics. He notes that tariffs could lead to strategic supply chain changes, including potential US manufacturing shifts. Digital health platforms like UpScriptHealth aim to reduce friction and costs in healthcare, potentially offsetting tariff impacts. Ax emphasizes the importance of telehealth in ensuring medication availability and the strategic partnerships between digital health platforms and pharma companies to improve patient care and access. He also praises Pfizer's approach to delivering comprehensive care rather than just selling medications.

Beyond cost, how might tariffs affect the availability and accessibility of specific medications, particularly for patients relying on direct-to-patient telehealth?

If you think about the way direct-to-patient telehealth works, is we allow a consumer to go on the web and talk to a clinician right away, assuming they're prescribed some medication, then we have to somehow assure availability, or at least have some insight into availability.

One of the real benefits of our platform is that we're able to partner with pharmaceutical companies to be sure that we have supply available, or that they've partnered with a fulfillment partner that is assured to have supply available. In a lot of ways, we can solve kind of nuances in the market that makes supply difficult because of tariffs. Think about a pharma company that enlists engages with UpScript to develop a platform. We end up partnering with a fulfillment partner, and we can assure the supply through that fulfillment partner, because we're dealing with the manufacturer, and the manufacturer can help make sure that medications are accessible. So, in a lot of ways, telehealth can mitigate the impact of tariffs and the and the changes in supply that may occur.

I think only time will tell which medications it impacts and how it impacts, whether it impacts generic drugs more than it does branded drugs. There will, of course, be some level of impact, but it won't be across the board. It's going to be in different pockets, for example. It will be easier to get medication in New York City than it is in Des Moines, Iowa, for example, and so telehealth can help sort of mitigate those differences.

In this Pharmaceutical Executive Video Interview, Peter Ax, Founder & CEO of UpScriptHealth, explores how tariffs could affect the availability and accessibility of specific medications, particularly for patients relying on direct-to-patient telehealth.

Jen Butler, Chief Commercial Officer for Pleio, discusses why pharma increasingly turning to peer-to-patient platforms to educate patients, as well as relationships with trusted patient communities and pharmacies.

Pharma’s Turn to Peer-to-Patient Platforms and Trusted Patient Communities

 video interview, Jen Butler, Chief Commercial Officer for Pleio, discussed the significant threat of misinformation to public health, citing a 2021 report by former Surgeon General Murthy. She highlighted that 70% of false news is shared more often than true news due to its emotional appeal. Butler emphasized the importance of verifying health information by directly contacting trusted sources like Cleveland Clinic, Mayo Clinic, and Kaiser Permanente. She also noted the role of pharma in supporting patient communities and the need for media and health literacy. Butler also suggested that peer-to-patient platforms can enhance patient engagement and adherence, particularly for chronic conditions.

How and why is pharma increasingly turning to peer-to-patient platforms to educate patients — as well as relationships with trusted patient communities and pharmacies?

The power of the human connection in a world that's so digital, really helps to cut through the noise and “unoverwhelm” the patients, if you will. I think that we can get lost in so many different areas of finding information and to just cut right through it, to have a conversation directly with a patient, to really listen and understand the level which a patient is where they need the information, making it relevant to the patient. Not every patient needs to be sent all the information, and there's little chunks of it that might be more worthwhile in understanding kind of what's needed at what time. I mean, focusing in the beginning onboarding patients is super important, as we see that, the medication adherence lasts a lot longer when you have the right setup to patients as they're onboarding.

A peer-to-patient creates a validated, trusted rapport. It's like a mentorship, if you will, where the peers are, what 

 would call ‘lay people’ and not white coats, not clinical and I say this because there's just another recent study done in December with 

 reported that diabetes patients who had support with a lay person actually saw significant improvements in their overall health and outcomes. It shows that just having that that support and rapport from a trusted source to just check in and make sure that everything is going in a direction that patient is looking to go in with resources and introducing resources that might be available that patients aren't aware of a lot of times, peer-to-patient platforms aren't always for those patients that are seeking out like a patient community. A patient has its fabulous community for patients who are seeking out others like them and that's a great source to go, to feel the support, to ask the questions, but not all patients are going to seek that information. So a peer-to-patient platform has more of a direct identification of patients and a reason behind the kind of that connection to make.

For example, with medication refills through pharmacies, pharmacies want to make sure that patients are getting their refills. Those refill check in reminders and check ins offer a whole conversation that can happen in support network for patients’ events, and that's where having a peer-to-patient platform to support that process can then also open up further discussions and develop that trusted rapport. That kind of starts in partnership with pharmacies and then brings in the brand medication sponsored needs as well but delivered through someone like them. Someone who's not a clinician, kind of mitigating that white coat syndrome, so if they're conditions that you want to talk about, that you might — let's just be honest, like when you go to your doctor and you and they ask you know your habits and your lifestyles, you might kind of curve it a little bit in the healthy way — when you have someone on the phone that's like you, you might not hold back like that. And that's where this conversation with someone that's a peer really is impactful. And you can develop that rapport, to say, build the confidence in taking that next step forward.

In this Pharmaceutical Executive video interview, Jen Butler, Chief Commercial Officer for Pleio, discusses why pharma increasingly turning to peer-to-patient platforms to educate patients, as well as relationships with trusted patient communities and pharmacies.

Peter Ax, Founder & CEO of UpScriptHealth, identifies strategies that pharmaceutical companies and digital health platforms can employ to navigate a potential drop in demand due to tariff-induced increased costs. 

How Pharmaceutical Companies Can Mitigate a Potential Drop in Demand Due to Tariffs

Tariffs could impact consumer demand. What strategies can pharmaceutical companies and digital health platforms like UpScriptHealth employ to mitigate this potential drop in demand due to increased costs?

Tariffs will increase costs — short run and long run — and will have different effects on the supply curve. But the bigger issue is, how do we solve the systemic problems that are involved in healthcare? And that's where digital platforms like UpScriptHealth (UpScript) come into play. The number one thing we have to do is take the friction and cost out of the system, and that's what we do every single day. We make trained clinicians available to patients right away. We make the insurance reimbursement process a lot simpler in terms of: we'll process the prior authorization for patients. We’ll process a lot of things behind the scenes to help the patient get on therapy as fast as they can.

So, we sort of take friction out of the system, and that's really going to be the job of digital health companies like UpScript, and that's going to continue to be the job. Take costs out of the system, take friction out of the system, make medications accessible, and if we can take some costs out of the system, we might actually offset any effect the tariffs have.

In this part of his Pharmaceutical Executive Video Interview, Peter Ax, Founder & CEO of UpScriptHealth, identifies strategies that pharmaceutical companies and digital health platforms can employ to navigate a potential drop in demand due to tariff-induced increased costs.

Jen Butler, Chief Commercial Officer for Pleio, the role pharma should be playing in helping to ensure patients have access to health insights they can trust.

Pharma’s Role in Ensuring Patient Access to Trustworthy Health Insights

What role can/should Pharma play in helping to ensure patients have access to health insights they can trust?

There's such a fine line that pharma is figuring out when you're referring to online patient communities. I've spoken to a couple online patient communities, and because when we're looking at kind of peer to patient and peer-to-peer platforms. Pharma has to make sure that they're supporting patients with education and content that's been MLR approved, and that they're supporting patients — that's not necessarily attracting and encouraging adverse event reporting. I think it's a very tricky line, and I agree with you, go to where the patients are talking, support them with the facts. 

You just have to be careful with the way that we've set up our requirements as well. Because if what we hear and the whole power is listening to patients, but what we hear also then will require another set of actions. It's a fine line that we play is with pharma coming into patient conversations, but there has to be some sort of middle ground where pharma can start to support patient communities in a way that provides the facts and dispels the opinions and myths that are going on.

I think that pharma has invested so much and so much behind information and resources to patients, and patients are really unaware of a lot of the resources that are available to them. A couple years ago, Freja did a report that said, I think only 23% of patients are aware of the information available to them and the resources. So, to your point, if pharma could somehow involve themselves in patient conversations and communities and let them know about resources that are available, I think it's been a tricky way of building in a traditional way of building the resources for patients to come, but patients are seeking out other patients for support and advice also. So how do we start to change that direction and support with parameters and requirements that are in place with pharma and healthcare organizations overall.

In this Pharmaceutical Executive video interview, Jen Butler, Chief Commercial Officer for Pleio, the role pharma should be playing in helping to ensure patients have access to health insights they can trust.

Jen Butler, Chief Commercial Officer for Pleio, shares some  best practices on finding trustworthy and verified information about a new prescription or medical device.

Verifying Information about New Prescriptions or Medical Devices

Can you share some insights on best practices about a new prescription or medical device?

The practice is again traditional and very basic, but I'll go into a little bit more explanation behind it is. But go to your trusted healthcare provider with a new medication and therapy and questions. That's absolutely the number one golden rule. But that's not always accessible to everybody, right? And your time with your healthcare provider is sometimes limited, but you just want to make sure that you're validating the new therapies, new approaches, beyond what you're hearing in whatever TikTok or AI generated content that you're reacting to.

I'll use GLP-1s as an example, because I think the recently, and what I didn't mention earlier in this is, GLP-1s is kind of that next surgence of massive misinformation. This amazing miracle drug that will have a huge impact on public health, but we have to make sure that the right patients are receiving the right diagnosis with the right medications. There's a lot of you know, I went on TikTok just to look at the fact there are over a dozen categories of GLP-1 discussions going on in videos and ways to find out information. There's also information out there that could be misleading regarding where to access GLP-1s and the compounding GLP-1 sites that you can now access the medications from and get it so far more easily, but not recognizing that there's false claims out there that these compounds are have FDA approval, and these are really important facts, again, versus the opinions of others that might be on these that need to be verified.

 actually just published in January on their health forum a letter acknowledging that this is becoming a concern as well, with patients going through the compound sites, again, just being aware and educated as a patient, as you said before having kind of that consumer education approach as a patient. I mean, patients are people, consumers. We're consuming healthcare. We need to make sure that we're putting the right approaches in place. So, I mentioned

. They're a great resource as well, tons of research. Health literacy might be a little bit elevated in some of the research that they put out there, but you can, at least get extracts and summaries as well of their research reports.

In this Pharmaceutical Executive video interview, Jen Butler, Chief Commercial Officer for Pleio, shares some  best practices on finding trustworthy and verified information about a new prescription or medical device.

Patient Access

Latest News